A/Prof Adnan Nagrial
MBBS FRACP PhD
Specialties
Medical Oncologist
Academic Appointments
Adnan Nagrial is a consultant Medical Oncologist, specialising in gastrointestinal and thoracic cancers. He is appointed to Westmead and Blacktown Hospitals as a Staff Specialist Medical Oncologist. He is a Clinical Associate Professor at the Sydney Medical School, University of Sydney.
Adnan graduated in medicine from the University of Melbourne. He trained at Westmead and Royal Prince Alfred Hospitals in Sydney after which he joined the Pancreas Cancer Research Group at The Garvan Institute of Medical Research in 2011. He spent the next four years working in a translational research laboratory to identify new treatments for Pancreas Cancer. He gained his PhD in Translation Genomics in Pancreatic Cancer in 2016.
He became a Fellow of the Royal Australian College of Physicians in 2012. He continues to practice in the medical treatment of gastrointestinal and thoracic cancers at Westmead, Blacktown and Norwest Hospitals. He is a clinical trial investigator and has been a principal investigator in over 30 clinical trials of new cancer treatments. He continues his translational research at Westmead Hospital and collaborates with colleagues both nationally and internationally.
Rooms for Consultations
Westmead Cancer Care Centre - Tel: 8890 5200
Hospitals Visited
Blacktown Public Hospital
Westmead Public Hospital
Norwest Private Hospital
Westmead Private Hospital
Research Interests
Thoracic Cancers
Gastrointestinal Cancers
Other Positions Held
Associate Professor Nagrial is a member of the Medical Oncology Group (Australia). He is a Member of the American Society of Clinical Oncology, the American Association for Cancer Research and the International Association for the study of Lung Cancer. He is an active member of the Australsian Gastro-Intestinal Trials Group (AGITG) and the Australasian Lung Cancer Trials Grop (ALTG). He is on several committees of the Royal Australian College of Physicans and has a major role in training medical students and medical oncology trainees.